NewAmsterdam Pharma Company N.V. Ordinary Shares

Company Profile

NewAmsterdam Pharma Company N.V. Ordinary Shares had its IPO on 2022-11-23 under the ticker symbol NAMS.

The company operates in the Healthcare sector and Biotechnology industry. NewAmsterdam Pharma Company N.V. Ordinary Shares has a staff strength of 22 employees.

Stock update

Shares of NewAmsterdam Pharma Company N.V. Ordinary Shares opened at $10 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $9.67 - $10.14, and closed at $9.88.

This is a -1.1% slip from the previous day's closing price.

A total volume of 15,292 shares were traded at the close of the day’s session.

In the last one week, shares of NewAmsterdam Pharma Company N.V. Ordinary Shares have slipped by -5.27%.

NewAmsterdam Pharma Company N.V. Ordinary Shares's Key Ratios

NewAmsterdam Pharma Company N.V. Ordinary Shares has a market cap of $858.64 million, indicating a price to book ratio of 4.1582 and a price to sales ratio of 11.0536.

In the last 12-months NewAmsterdam Pharma Company N.V. Ordinary Shares’s revenue was $13.56 million with a gross profit of $0 and an EBITDA of $-137619008. The EBITDA ratio measures NewAmsterdam Pharma Company N.V. Ordinary Shares's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, NewAmsterdam Pharma Company N.V. Ordinary Shares’s operating margin was -1014.78% while its return on assets stood at -24.97% with a return of equity of -68.46%.

In Q2, NewAmsterdam Pharma Company N.V. Ordinary Shares’s quarterly earnings growth was a positive 0% while revenue growth was a negative 89.8%.

NewAmsterdam Pharma Company N.V. Ordinary Shares’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-2.63 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into NewAmsterdam Pharma Company N.V. Ordinary Shares’s profitability.

NewAmsterdam Pharma Company N.V. Ordinary Shares stock is trading at a EV to sales ratio of 7.65 and a EV to EBITDA ratio of 20.0313. Its price to sales ratio in the trailing 12-months stood at 11.0536.

NewAmsterdam Pharma Company N.V. Ordinary Shares stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$471.10 million

Total Liabilities

$38.34 million

Operating Cash Flow

$0

Capital Expenditure

$3250

Dividend Payout Ratio

0%

NewAmsterdam Pharma Company N.V. Ordinary Shares ended 2024 with $471.10 million in total assets and $0 in total liabilities. Its intangible assets were valued at $471.10 million while shareholder equity stood at $422.26 million.

NewAmsterdam Pharma Company N.V. Ordinary Shares ended 2024 with $0 in deferred long-term liabilities, $38.34 million in other current liabilities, 608754000.00 in common stock, $-194463000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $383.50 million and cash and short-term investments were $383.50 million. The company’s total short-term debt was $64,000 while long-term debt stood at $0.

NewAmsterdam Pharma Company N.V. Ordinary Shares’s total current assets stands at $389.26 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $5.77 million compared to accounts payable of $20.85 million and inventory worth $0.

In 2024, NewAmsterdam Pharma Company N.V. Ordinary Shares's operating cash flow was $0 while its capital expenditure stood at $3250.

Comparatively, NewAmsterdam Pharma Company N.V. Ordinary Shares paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$9.88

52-Week High

$18.7

52-Week Low

$7.52

Analyst Target Price

$22.52

NewAmsterdam Pharma Company N.V. Ordinary Shares stock is currently trading at $9.88 per share. It touched a 52-week high of $18.7 and a 52-week low of $18.7. Analysts tracking the stock have a 12-month average target price of $22.52.

Its 50-day moving average was $11.14 and 200-day moving average was $12.1 The short ratio stood at 2.13 indicating a short percent outstanding of 0%.

Around 653.5% of the company’s stock are held by insiders while 6990.8% are held by institutions.